-
| ISIN | US87807D1037 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | PINK |
| CurrencyCode | USD |
| PE Ratio | None |
|---|---|
| Target Price | 48 |
| Market Cap | 256K |
| Beta | 0.01 |
| Dividend Yield | None |
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TCBP using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025